Cvijic Christine Mikail 4

What Happened

• Christine Mikail Cvijic, President and Chief Financial Officer of Neurogene Inc., reported three open-market sales on March 13, 2026 totaling 4,045 shares for aggregate proceeds of approximately $84,176. These sales were mandatory share-withholdings to cover tax obligations when a restricted stock unit (RSU) partially vested.

Key Details

• Transaction date: March 13, 2026 (Form 4 filed March 17, 2026 — timely).
• Sales (all reported as S = Sale):
  • 2,387 shares @ weighted avg $20.42 (range $19.92–$20.87), proceeds ~$48,748. (F2)
  • 1,395 shares @ weighted avg $21.25 (range $20.92–$21.91), proceeds ~$29,637. (F4)
  • 263 shares @ weighted avg $22.02 (range $21.92–$22.075), proceeds ~$5,791. (F5)
• Total shares sold: 4,045; total proceeds: ~$84,176.
• Holdings reported after the transaction (per footnote F3): includes unvested RSUs — 10,635 RSUs (granted 3/13/2024, vest 3/13/2027), 20,300 RSUs (granted 3/26/2025, vest in equal installments 2026–2028), 22,000 RSUs (granted 2/20/2026, vest in equal installments 2027–2029) — and 19,200 shares held jointly with spouse David Cvijic.
• Notable footnote: F1 states these sales were automatic (no election by the reporting person) to satisfy tax withholding triggered by the RSU vesting.

Context

• These sales were for tax withholding on vested RSUs (routine administrative sales), not discretionary open-market selling by choice; such transactions are common when equity awards vest. They do not necessarily signal executive sentiment about the company. The filing shows the insider remains substantially invested through unvested RSUs and jointly held shares.